超选择性动脉内输注顺铂后联合治疗上颌鳞状细胞癌。
Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma.
作者信息
Shiga Kiyoto, Yokoyama Junkichi, Hashimoto Sho, Saijo Shigeru, Tateda Masaru, Ogawa Takenori, Watanabe Mika, Kobayashi Toshimitsu
机构信息
Department of Otolaryngology-Head and Neck Surgery, Tohoku University Hospital, Sendai, Japan.
出版信息
Otolaryngol Head Neck Surg. 2007 Jun;136(6):1003-9. doi: 10.1016/j.otohns.2006.12.018.
OBJECTIVE
We sought to assess the efficacy of combined therapy after superselective arterial cisplatin infusion (SACI) therapy to treat the maxillary squamous cell carcinoma.
STUDY DESIGN
We conducted a retrospective chart review of 50 patients. After completion of two courses of SACI, 25 of the patients were successively treated by concurrent SACI and radiotherapy (AR), while the other 25 patients were treated by surgery with postoperative radiotherapy (ASR).
RESULTS
Patients with surgery (ASR) had an 88% local control rate with 75% disease-free survival rate at 60 months by Kaplan-Meier analysis, compared with 62% disease-free survival rate for patients with AR treatment. A particularly good outcome was obtained in T4 cases of the ASR group (n=8) whose 5-year survival rate was 87% and local control rate was 100%.
CONCLUSION/SIGNIFICANCE: Combined SACI therapy is very effective for the treatment of maxillary squamous cell carcinomas and contributes to the improving prognoses of patients and organ preservation rates.
目的
我们旨在评估超选择性动脉顺铂灌注（SACI）治疗后联合治疗在上颌鳞状细胞癌治疗中的疗效。
研究设计
我们对50例患者进行了回顾性病历审查。在完成两个疗程的SACI后，25例患者先后接受同步SACI和放疗（AR），而另外25例患者接受手术加术后放疗（ASR）。
结果
通过Kaplan-Meier分析，接受手术（ASR）的患者60个月时局部控制率为88%，无病生存率为75%，而接受AR治疗的患者无病生存率为62%。ASR组的T4病例（n = 8）取得了特别好的结果，其5年生存率为87%，局部控制率为100%。
结论/意义：联合SACI治疗在上颌鳞状细胞癌的治疗中非常有效，有助于改善患者的预后和器官保留率。
Zotero 插件